3.12
0.20 (6.68%)
| Penutupan Terdahulu | 2.92 |
| Buka | 3.04 |
| Jumlah Dagangan | 911,101 |
| Purata Dagangan (3B) | 1,398,132 |
| Modal Pasaran | 428,589,696 |
| Harga / Jualan (P/S) | 321.64 |
| Harga / Buku (P/B) | 2.20 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -6,661.77% |
| EPS Cair (TTM) | -0.360 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.30% |
| Nisbah Semasa (MRQ) | 14.96 |
| Aliran Tunai Operasi (OCF TTM) | -44.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -27.80 M |
| Pulangan Atas Aset (ROA TTM) | -23.81% |
| Pulangan Atas Ekuiti (ROE TTM) | -36.07% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Compass Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.13 |
|
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 18.08% |
| % Dimiliki oleh Institusi | 70.99% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 32.00 (D. Boral Capital, 927.29%) | Beli |
| Median | 11.00 (253.13%) | |
| Rendah | 6.00 (Leerink Partners, 92.62%) | Beli |
| Purata | 13.33 (327.93%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 2.50 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 02 Apr 2025 | 12.00 (285.23%) | Beli | 1.99 |
| 24 Feb 2025 | 12.00 (285.23%) | Beli | 3.11 | |
| Leerink Partners | 02 Apr 2025 | 6.00 (92.62%) | Beli | 1.99 |
| D. Boral Capital | 01 Apr 2025 | 32.00 (927.29%) | Beli | 1.99 |
| 27 Feb 2025 | 32.00 (927.29%) | Beli | 2.92 | |
| Piper Sandler | 19 Feb 2025 | 12.00 (285.23%) | Beli | 3.38 |
| Jefferies | 10 Feb 2025 | 8.00 (156.82%) | Beli | 3.90 |
| HC Wainwright & Co. | 10 Jan 2025 | 10.00 (221.03%) | Beli | 1.77 |
| 08 Jan 2025 | 10.00 (221.03%) | Beli | 1.86 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Apr 2025 | Pengumuman | Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum |
| 01 Apr 2025 | Pengumuman | Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer |
| 31 Mar 2025 | Pengumuman | Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer |
| 27 Feb 2025 | Pengumuman | Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update |
| 29 Jan 2025 | Pengumuman | Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference |
| 08 Jan 2025 | Pengumuman | Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |